JP7706775B2 - アミン誘導体 - Google Patents

アミン誘導体 Download PDF

Info

Publication number
JP7706775B2
JP7706775B2 JP2022550631A JP2022550631A JP7706775B2 JP 7706775 B2 JP7706775 B2 JP 7706775B2 JP 2022550631 A JP2022550631 A JP 2022550631A JP 2022550631 A JP2022550631 A JP 2022550631A JP 7706775 B2 JP7706775 B2 JP 7706775B2
Authority
JP
Japan
Prior art keywords
benzothiazol
dihydrofuro
optionally substituted
imidazol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022550631A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022059779A5 (https=
JPWO2022059779A1 (https=
Inventor
慎吾 東城
大輔 浦辺
仁 渡辺
亘 川畑
英樹 森山
優子 朝光
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carna Biosciences Inc
Original Assignee
Carna Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carna Biosciences Inc filed Critical Carna Biosciences Inc
Publication of JPWO2022059779A1 publication Critical patent/JPWO2022059779A1/ja
Publication of JPWO2022059779A5 publication Critical patent/JPWO2022059779A5/ja
Priority to JP2025106969A priority Critical patent/JP2025134941A/ja
Application granted granted Critical
Publication of JP7706775B2 publication Critical patent/JP7706775B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022550631A 2020-09-18 2021-09-17 アミン誘導体 Active JP7706775B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025106969A JP2025134941A (ja) 2020-09-18 2025-06-25 アミン誘導体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020157398 2020-09-18
JP2020157398 2020-09-18
JP2021122893 2021-07-28
JP2021122893 2021-07-28
PCT/JP2021/034327 WO2022059779A1 (ja) 2020-09-18 2021-09-17 アミン誘導体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025106969A Division JP2025134941A (ja) 2020-09-18 2025-06-25 アミン誘導体

Publications (3)

Publication Number Publication Date
JPWO2022059779A1 JPWO2022059779A1 (https=) 2022-03-24
JPWO2022059779A5 JPWO2022059779A5 (https=) 2024-09-19
JP7706775B2 true JP7706775B2 (ja) 2025-07-14

Family

ID=80776131

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022550631A Active JP7706775B2 (ja) 2020-09-18 2021-09-17 アミン誘導体
JP2025106969A Pending JP2025134941A (ja) 2020-09-18 2025-06-25 アミン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025106969A Pending JP2025134941A (ja) 2020-09-18 2025-06-25 アミン誘導体

Country Status (10)

Country Link
US (1) US20230365589A1 (https=)
EP (1) EP4215534A4 (https=)
JP (2) JP7706775B2 (https=)
KR (1) KR20230069162A (https=)
CN (1) CN116209441A (https=)
AU (1) AU2021343770A1 (https=)
BR (1) BR112023003807A2 (https=)
CA (1) CA3191617A1 (https=)
MX (1) MX2023003245A (https=)
WO (1) WO2022059779A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023008470A1 (ja) * 2021-07-28 2023-02-02 住友ファーマ株式会社 縮環アミン誘導体
WO2025170029A1 (ja) * 2024-02-09 2025-08-14 カルナバイオサイエンス株式会社 ジヒドロキナゾリノン誘導体

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003521543A (ja) 2000-02-07 2003-07-15 アボット ゲーエムベーハー ウント カンパニー カーゲー ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用
JP2013510824A (ja) 2009-11-12 2013-03-28 セルビタ エス．エー． セリン／トレオニンキナーゼを調節または制御するための化合物、その調製のための方法、医薬組成物、化合物の使用、方法ならびにセリン／トレオニンキナーゼ調節剤
JP2014525928A (ja) 2011-08-19 2014-10-02 ディアクソンヒット Ｄｙｒｋ１阻害剤およびその使用
JP2015107945A (ja) 2013-12-05 2015-06-11 国立大学法人京都大学 神経新生に関する化合物及び医薬組成物
US20170007583A1 (en) 2014-02-04 2017-01-12 Lytix Biopharma As Neurodegenerative Therapies
JP2019531318A (ja) 2016-10-12 2019-10-31 ファーマスム セラピューティクス エイエス Ｄｙｒｋ１阻害剤としてのベンゾチアゾール誘導体
WO2021153665A1 (ja) 2020-01-30 2021-08-05 カルナバイオサイエンス株式会社 新規アルキン誘導体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1679308B1 (en) 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
WO2008021338A2 (en) * 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as pr modulators
JP2010163361A (ja) 2007-04-27 2010-07-29 Dainippon Sumitomo Pharma Co Ltd キノリン誘導体
KR20100010894A (ko) 2008-07-23 2010-02-02 가부시키가이샤 키노파마 Ｄｙｒｋ를 저해하는 화합물을 함유하는 의약 조성물
US8470835B2 (en) 2009-01-13 2013-06-25 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
CA2816219C (en) 2010-11-01 2019-10-29 Portola Pharmaceuticals, Inc. Nicotinamides as syk modulators
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
WO2013043002A1 (en) 2011-09-23 2013-03-28 Yuhan Corporation Imide-containing benzothiazole derivative or its salt and pharmaceutical composition comprising the same
KR101916443B1 (ko) 2012-07-26 2018-11-08 글락소 그룹 리미티드 Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸
RS63405B1 (sr) 2013-10-25 2022-08-31 Blueprint Medicines Corp Inhibitori receptora faktora rasta fibroblasta
JP2017516850A (ja) 2014-05-23 2017-06-22 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｊａｋ阻害剤である５−クロロ−２−ジフルオロメトキシフェニルピラゾロピリミジン化合物
WO2016044641A2 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Carm1 inhibitors and uses thereof
CN109206537B (zh) 2018-10-10 2021-04-09 华熙生物科技股份有限公司 一种乙酰化透明质酸钠的制备方法及其应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003521543A (ja) 2000-02-07 2003-07-15 アボット ゲーエムベーハー ウント カンパニー カーゲー ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用
JP2013510824A (ja) 2009-11-12 2013-03-28 セルビタ エス．エー． セリン／トレオニンキナーゼを調節または制御するための化合物、その調製のための方法、医薬組成物、化合物の使用、方法ならびにセリン／トレオニンキナーゼ調節剤
JP2014525928A (ja) 2011-08-19 2014-10-02 ディアクソンヒット Ｄｙｒｋ１阻害剤およびその使用
JP2015107945A (ja) 2013-12-05 2015-06-11 国立大学法人京都大学 神経新生に関する化合物及び医薬組成物
US20170007583A1 (en) 2014-02-04 2017-01-12 Lytix Biopharma As Neurodegenerative Therapies
JP2019531318A (ja) 2016-10-12 2019-10-31 ファーマスム セラピューティクス エイエス Ｄｙｒｋ１阻害剤としてのベンゾチアゾール誘導体
WO2021153665A1 (ja) 2020-01-30 2021-08-05 カルナバイオサイエンス株式会社 新規アルキン誘導体

Also Published As

Publication number Publication date
AU2021343770A9 (en) 2024-09-12
KR20230069162A (ko) 2023-05-18
MX2023003245A (es) 2023-04-11
JP2025134941A (ja) 2025-09-17
EP4215534A1 (en) 2023-07-26
US20230365589A1 (en) 2023-11-16
EP4215534A4 (en) 2024-10-02
BR112023003807A2 (pt) 2023-03-28
CA3191617A1 (en) 2022-03-24
CN116209441A (zh) 2023-06-02
JPWO2022059779A1 (https=) 2022-03-24
TW202227459A (zh) 2022-07-16
AU2021343770A1 (en) 2023-05-18
WO2022059779A1 (ja) 2022-03-24

Similar Documents

Publication Publication Date Title
US20220402915A1 (en) Bcl-2 inhibitors
US10442776B2 (en) 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
JP7819233B2 (ja) 三環式誘導体を含む阻害剤、その製造方法、及び使用
US10899752B2 (en) 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor
US11787803B2 (en) Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors
CA3163007A1 (en) Inhibitors of mutant forms of egfr
JP2025134941A (ja) アミン誘導体
JP2014528405A (ja) マクロ環状ｌｒｒｋ２キナーゼ阻害剤
US9453021B2 (en) Pyrimidodiazepinone compound
WO2021153665A1 (ja) 新規アルキン誘導体
US20250361241A1 (en) Hpk1 inhibitor and medical use thereof
JP2023138470A (ja) アミン誘導体を含有する医薬
TWI915421B (zh) 胺衍生物
HK40090757A (en) Amine derivative
EP4516793A1 (en) Piperidine carboxamide azaindane derivative, method for preparing same, and use thereof
US20250084098A1 (en) Fused-ring amine derivative
TW202604506A (zh) 四氫吡唑并吡啶衍生物
CN120548310A (zh) 具有双氮杂环取代的异吲哚啉酮骨架的化合物及其应用
HK40031697B (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
HK40031697A (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240910

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250110

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250514

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250527

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250625

R150 Certificate of patent or registration of utility model

Ref document number: 7706775

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150